Short- and long-term treatments with iloprost in diabetic patients with peripheral vascular disease: Effects on the cardiovascular risk factor plasminogen activator inhibitor type-1

European Journal of Clinical Pharmacology

Volumn 55, Issue 7, 1999, Pages 491-497

  Cozzolino, D ^a   Coppola, L ^a   Masi, S ^a   Salvatore, T ^a   Sasso, F C ^a   De Lucia, D ^a   Gentile, S ^a   Torella, R ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Plasminogen activator inhibitor type 1; Prostaglandin; Type 2 diabetes mellitus

Indexed keywords

FIBRINOGEN; GLUCOSE; ILOPROST; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; FIBRINOGEN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HEADACHE; HEART RATE; HEMOGLOBIN DETERMINATION; HUMAN; INSULIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; WALKING;

AGED; BLOOD GLUCOSE; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; FIBRINOGEN; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; ILOPROST; INSULIN; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; PILOT PROJECTS; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; WALKING;

EID: 0032879791     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050662     Document Type: Article

References (35)

1. Uusitupa MI, Niskanen LK, Siitonen O, Voutilainen E, Pyorala K (1990) 5-Year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin-dependent diabetic and nondiabetic subjects. Circulation 82: 27-36
2. Bierman EL (1992) Atherogenesis in diabetes. Arterioscler Thromb 12: 647-656
3. Amado JA, Salas E, Botana MA, Poveda JJ, Berrazueta JR (1993) Low levels of intraplatelet cGMP in IDDM. Diabetes Care 16: 809-811
4. Banga JD, Sixma JI (1986) Diabetes mellitus, vascular disease and thrombosis. Clin Hematol 15: 465-492
5. Schneider DJ, Nordt TK, Sobel BE (1993) Attenuated fibrinolysis and accelerated atherogenesis in type II diabetic patients. Diabetes 42: 1-7
6. Császár A, Dieplinger H, Sandholzer C et al. (1992) Plasma lipoprotein(a) concentration and phenotypes in diabetes mellitus. Diabetologia 36: 47-51
7. Juhan-Vague I, Alessi MC, Vague P (1991) Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 34: 457-462
8. Landin K, Tengborn L, Smith U (1990) Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Int Med 227: 273-278
9. Juhan-Vague I, Vague P, Alessi MC et al. (1987) Relationship between plasma insulin, triglyceride, body mass index and plasminogen activator inhibitor 1. Diabetes Metab 13: 331-336
10. Potter van Loon BJ, Kluft C, Radder JK, Blankenstein MA, Meinders AE (1993) The cardiovascular risk factor plasminogen activator inhibitor type 1 is related to insulin resistance. Metabolism 42: 945-949
11. Chiesa R, Vicari A, Mari G, Galimberti M, Dicarlo V, Pozza G (1985) Use of stable prostacyclin analogue ZK 36374 to treat severe lower limb ischemia. Lancet II: 95-96
12. Roberts DH, Linge K, Nixon DP et al. (1988) The effects of iloprost on calf blood flow in patients with stable intermittent claudication. Br J Clin Pharmacol 25: 148-149
13. Cowley AJ, Heptinstall S, Hampton JR (1985) Effects of prostacyclin and of the stable prostacyclin analogue ZK 36374 on forearm blood flow and blood platelet behaviour in man. Thromb Haemost 53: 90-94
14. Rose GA (1962) The diagnosis of ischaemic heart pain and intermittent claudication in field surveys. Bull World Health Organ 27: 645-658
15. Criqui MH, Fronek A, Klauber MR, Barret-Connor E, Gabriel S (1985) The sensitivity, specificity, and predictive value of traditional clinical evaluation of peripheral arterial disease: results from noninvasive testing in a defined population. Circulation 71: 516-522
16. Angleton P, Chandler WL, Schmer G (1989) Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor. Circulation 79: 101-106
17. von Clauss A (1957) Gerinnungsphysiologische schnellmethode zur bestimmung des fibrinogens. Acta Haematol 17: 237-246
18. Carter S (1968) Indirect systolic pressures and pulse waves in arterial occlusive disease of the lower extremities. Circulation 37: 624-637
19. Sprengers ED, Kluft C (1987) Plasminogen activator inhibitors. Blood 69: 381-387
20. Olofsson BO, Dahlén G, Nilsson TK (1989) Evidence for increased levels of plasminogen activator inhibitor and tissue plasminogen activator in plasma of patients with angiographically verified coronary artery disease. Eur Heart J 10: 77-82
21. De Lucia D, Di Mauro C, Renis V et al. (1995) Effetti dell'iloprost sulla cascata emocoagulativa e fibrinolitica in pazienti con storia di vasculopatia obliterante diabetica. Pat Clin 10: 578-583
22. Grant PJ, Ruegg M, Medealf RL (1991) Basal expression and insulin mediated induction of PAI-1 mRNA in Hep G2 cells. Fibrinolysis 5: 81-86
23. Padayatty SJ, Orme S, Zenobi PD, Stickland MH, Belchetz PE, Grant PJ (1993) The effects of insulin-like growth factor-1 on plasminogen activator inhibitor-1 synthesis and secretion: results from in vitro and in vivo studies. Thromb Haemost 70: 1009-1013
24. Maiello M, Boeri D, Podesta F et al. (1992) Increased expression of tissue plasminogen activator and its inhibitor and reduced fibrinolytic potential of human endothelial cells cultured in elevated glucose. Diabetes 41: 1009-1015
25. Nordt TK, Klassenk J, Schneider DJ, Sobel BE (1993) Augmentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implications for local fibrinolysis. Arterioscler Thromb 13: 1822-1828
26. Paolisso G, Di Maro G, D'Amore A et al. (1995) Low-dose iloprost infusion improves insulin action in aged healthy subjects and NIDDM patients. Diabetes Care 18: 200-205
27. Gough SCL, Grant PJ (1991) The fibrinolytic system in diabetes mellitus. Diabet Med 8: 898-905
28. 2-dependent platelet activation. Prostaglandins 36: 751-760
29. Musial J, Wilczynska M, Sladek K, Cierniewski SC, Nizaukowski R, Szczeblek A (1986) Fibrinolytic activity of prostacyclin and iloprost in patients with peripheral arterial disease. Prostaglandins 31: 61-70
30. Ferlito S, Di Salvo MM, Attanasio L, Finocchiaro PM, Condorelli PM, Mazzone D (1994) Plasma prothrombotic markers after a short- and middle term treatment with iloprost in arteriopathic patients with critical limb ischemia. Panminerva Med 36: 76-79
31. Krause W, Krais T (1986) Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man. Eur J Clin Pharmacol 30: 61-68
32. Ceriello A, Sardina M, Motz E, Lizzio S, Tuniz D, Bianchini C (1998) Effects of iloprost, either administered for 1 week or 4 weeks, on systemic hemodynamics, peripheral blood flow, and exercise tolerance in patients with peripheral occlusive arterial disease at Leriche-Fontaine stage III. Int J Angiol 7: 28-33
33. 2 and endothelin. Angiology 48: 149-155
34. Caspary I, Creutzig A, Alexander K (1991) Intravenous infusion of iloprost in arterial occlusive disease: dose-dependent effects on skin microcirculation. Eur J Clin Pharmacol 41: 131-136
35. Shindo H, Tawata M, Yokomori N, Hosaka Y, Ohtaka M, Onaya T (1993) Iloprost decreases urinary albumin excretion rate in patients with diabetic nephropathy. Diabetes Res Clin Pract 21: 115-122